Inactive Instrument
PHAXIAM Therapeutics S.A. Stock
Stocks
PHXM
FR001400K4B1
Biotechnology & Medical Research
OTC Markets Traded
| Manager | Title | Age | Since |
|---|---|---|---|
Thibaut du Fayet
CEO | Chief Executive Officer | 58 | 2023-06-22 |
Eric Soyer
DFI | Director of Finance/CFO | 59 | 2023-06-22 |
Cindy Fevre
CTO | Chief Tech/Sci/R&D Officer | - | 2023-06-22 |
| Director | Title | Age | Since |
|---|---|---|---|
Didier Hoch
CHM | Chairman | 70 | 2023-06-22 |
| Director/Board Member | 66 | 2023-06-22 | |
Martine George
BRD | Director/Board Member | 78 | 2023-06-22 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 1.16M | |
| +4.16% | +3.04% | +49.37% | +94.17% | 74.16B | |
| -3.11% | -3.53% | +20.19% | +81.44% | 57.39B | |
| +0.89% | -0.63% | +2.17% | +36.19% | 47.64B | |
| +0.36% | +0.81% | +342.39% | +742.40% | 44.29B | |
| -0.96% | -4.50% | +24.96% | +35.38% | 42.5B | |
| -0.20% | -0.77% | +4.13% | +105.50% | 40.71B | |
| -0.54% | +2.93% | +9.31% | +50.41% | 30.97B | |
| -2.68% | +2.92% | +29.33% | +22.72% | 28.53B | |
| +0.05% | -1.64% | -8.14% | -11.37% | 24.34B | |
| Average | -0.20% | -0.59% | +52.63% | +128.54% | 43.39B | |
| Weighted average by Cap. | +0.12% | -0.84% | +56.96% | +138.26% |
Employees
68
